Neuphoria Therapeutics Inc. Increase Decrease In Operating Lease Liability
Neuphoria Therapeutics Inc. (NEUP) reported Increase Decrease In Operating Lease Liability of -$116.31 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-09-18
- Neuphoria Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was $0.00.
- Neuphoria Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was $0.00.
- Neuphoria Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$85.21K.
- Neuphoria Therapeutics Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$31.10K.
- Neuphoria Therapeutics Inc. increase decrease in operating lease liability for fiscal 2026 was -$116.31K.
- Neuphoria Therapeutics Inc. increase decrease in operating lease liability for fiscal 2025 was -$123.30K.
- Neuphoria Therapeutics Inc. increase decrease in operating lease liability for fiscal 2024 was -$114.15K.
- Neuphoria Therapeutics Inc. increase decrease in operating lease liability for fiscal 2023 was -$107.81K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $0.00 derived: sum of 2 quarters · filed 2026-09-18 | -$85.21K derived: sum of 3 quarters · filed 2026-09-18 | -$116.31K 10-K · filed 2026-09-18 |
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$85.21K derived: sum of 2 quarters · filed 2026-05-15 | -$116.31K 10-Q · filed 2026-05-15 | -$141.06K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | -$85.21K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$116.31K 10-Q · filed 2026-02-17 | -$141.06K derived: sum of 3 quarters · filed 2026-09-18 | -$168.31K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | -$31.10K 10-Q · filed 2025-11-14 | -$55.85K derived: sum of 2 quarters · filed 2026-09-18 | -$83.10K derived: sum of 3 quarters · filed 2026-09-18 | -$134.14K derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | -$24.75K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$52.00K derived: sum of 2 quarters · filed 2026-09-18 | -$103.04K derived: sum of 3 quarters · filed 2026-09-18 | -$123.30K 10-K · filed 2026-09-18 |
| 2025-03-31 | -$27.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | -$78.29K derived: sum of 2 quarters · filed 2026-05-15 | -$98.56K 10-Q · filed 2026-05-15 | -$123.90K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$51.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | -$71.31K 10-Q · filed 2026-02-17 | -$96.65K derived: sum of 3 quarters · filed 2026-02-17 | -$138.68K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$20.27K 10-Q · filed 2025-11-14 | -$45.61K derived: sum of 2 quarters · filed 2025-11-14 | -$87.64K derived: sum of 3 quarters · filed 2025-11-14 | -$98.02K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$25.35K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$67.37K derived: sum of 2 quarters · filed 2025-09-29 | -$77.75K derived: sum of 3 quarters · filed 2025-09-29 | -$114.15K 10-K · filed 2025-09-29 |
| 2024-03-31 | -$42.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | -$52.41K derived: sum of 2 quarters · filed 2025-05-20 | -$88.80K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$10.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$46.78K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | -$36.39K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$107.81K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |